Holen Sie sich die Stockscreener-App
1.845
3.07%
0.055
Schlusskurs vom Vortag:
$1.79
Offen:
$1.81
24-Stunden-Volumen:
489.90K
Relative Volume:
0.35
Marktkapitalisierung:
$276.55M
Einnahmen:
$42.17M
Nettoeinkommen (Verlust:
$-183.12M
KGV:
-1.267
EPS:
-1.4562
Netto-Cashflow:
$-138.51M
1W Leistung:
+6.03%
1M Leistung:
+10.48%
6M Leistung:
+23.83%
1J Leistung:
+98.41%
1-Tages-Spanne:
$1.76
$1.87
1-Wochen-Bereich:
$1.73
$1.87
52-Wochen-Spanne:
$0.71
$2.6158
Coherus Oncology Inc Stock (CHRS) Company Profile
Firmenname
Coherus Oncology Inc
Sektor
Branche
Telefon
(650) 649-3530
Adresse
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.845 | 268.30M | 42.17M | -183.12M | -138.51M | -1.4562 |
VRTX
Vertex Pharmaceuticals Inc
|
425.06 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.92 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.26 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.47 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.76 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-23 | Eingeleitet | Oppenheimer | Outperform |
| 2025-09-04 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-08-16 | Herabstufung | UBS | Buy → Neutral |
| 2023-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2023-07-24 | Eingeleitet | Citigroup | Buy |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2023-03-28 | Hochstufung | UBS | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Neutral |
| 2022-03-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Eingeleitet | BofA Securities | Neutral |
| 2020-04-17 | Eingeleitet | SunTrust | Buy |
| 2019-08-13 | Eingeleitet | Mizuho | Buy |
| 2019-08-02 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-02 | Bestätigt | Maxim Group | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-09 | Bestätigt | Maxim Group | Buy |
| 2017-08-08 | Bestätigt | JP Morgan | Overweight |
| 2017-06-13 | Bestätigt | Maxim Group | Buy |
| 2017-05-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2016-10-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-09-07 | Eingeleitet | Maxim Group | Buy |
| 2016-07-27 | Eingeleitet | Citigroup | Buy |
| 2016-01-20 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Coherus Oncology Inc Aktie (CHRS) Neueste Nachrichten
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? - Yahoo! Finance Canada
Coherus Oncology (CHRS) to Release Q1 2026 Financial Results - GuruFocus
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026 - The Manila Times
Coherus sets May 11 after-close call for Q1 results, business update - Stock Titan
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200-Day Moving AverageHere's Why - MarketBeat
Hepatic Tumor Pipeline Grows as 75+ Pharma Companies Advance - openPR.com
Satterfield reports 6.93M shares in Coherus Oncology (NASDAQ: CHRS) ownership filing - Stock Titan
BlackRock reports 4.9% stake in Coherus Oncology (CHRS) - Stock Titan
Coherus Oncology announces proposed public offering of common stock - MSN
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above 200 Day Moving AverageHere's Why - MarketBeat
CHRS Price Today: Coherus Oncology, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Coherus Oncology prices stock offering to raise $50.1M - MSN
Is Coherus (CHRS) stock losing upward momentum (Bullish Sentiment) 2026-04-20Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Lào Cai
[ARS] Coherus Oncology, Inc. SEC Filing - Stock Titan
[DEF 14A] Coherus Oncology, Inc. Definitive Proxy Statement - Stock Titan
Coherus (CHRS) Stock Signal Based Trade (Bullish Momentum) 2026-04-16Professional Trade Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Is Brookdale Senior Living (BKD) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Coherus Oncology (CHRS) is one of the best penny stocks, here is why – corrected - MSN
Coherus Oncology Inc (STU:8C5) Stock Price & 30 Year Financial Data - GuruFocus
Certain Warrants of Coherus Oncology, Inc. are subject to a Lock-Up Agreement Ending on 14-APR-2026. - marketscreener.com
Certain Stock Options of Coherus Oncology, Inc. are subject to a Lock-Up Agreement Ending on 14-APR-2026. - marketscreener.com
Certain Common Stock of Coherus Oncology, Inc. are subject to a Lock-Up Agreement Ending on 14-APR-2026. - marketscreener.com
CHRS SEC FilingsCoherus 10-K, 10-Q, 8-K Forms - Stock Titan
What should investors watch in Coherus (CHRS) Stock | Price at $1.66, Down 1.49%Trader Community Insights - Xã Vĩnh Công
Coherus Oncology (CHRS) Is One of the Best Penny Stocks, Here is Why – Corrected - Yahoo Finance
Coherus Oncology (CHRS) proposes option repricing and 7.7M-share increase - Stock Titan
Coherus Oncology Receives 'Hold' Rating from Analysts - National Today
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Why The Coherus Oncology (CHRS) Story Is Shifting Around Growth Assumptions And Execution Risk - Yahoo Finance
Coherus Oncology (CHRS) upgraded to buy: Here's what you should know - msn.com
Vanguard disaggregates holdings; 0% stake in Coherus (NASDAQ: CHRS) - Stock Titan
If You Invested $1,000 in Coherus (CHRS) - Stock Titan
Metastatic Hepatocellular Carcinoma Clinical Trial Pipeline - openpr.com
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Coherus Oncology (NASDAQ:CHRS) Shares Pass Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
CHRS Technical Analysis & Stock Price Forecast - Intellectia AI
Coherus BioSciences Q4 2025 earnings preview - MSN
Coherus Oncology (CHRS) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf. - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Upgraded at Wall Street Zen - MarketBeat
Coherus Oncology, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Coherus Oncology (CHRS) price target increased by 13.33% to 5.78 - MSN
Finanzdaten der Coherus Oncology Inc-Aktie (CHRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):